Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00108862 |
The purpose of this study is to determine the best time to begin anti-HIV treatment in individuals who have HIV and tuberculosis (TB).
Study hypothesis: Immediate antiretroviral therapy (ART), initiated within approximately 2 weeks after initiation of TB treatment, will reduce the frequency of other AIDS-defining illnesses and death in HIV infected participants being treated for TB by at least 40% by Week 48 when compared to deferred ART initiated at least 8 weeks after initiation of TB treatment.
Condition | Intervention |
---|---|
HIV Infections Tuberculosis |
Drug: Efavirenz Drug: Emtricitabine Drug: Emtricitabine/Tenofovir disoproxil fumarate Drug: Tenofovir disoproxil fumarate Drug: Rifampin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for HIV Infected Persons Treated for Tuberculosis With CD4 Less Than 200 Cells/mm3 |
Estimated Enrollment: | 800 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | July 2013 |
Estimated Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1A: Experimental
Participants will initiate ART within 2 weeks after initiating TB treatment. Participants in Arm 1A will not enroll in Arm 2.
|
Drug: Efavirenz
600 mg tablet taken orally daily
Drug: Emtricitabine
200 mg tablet taken orally daily
Drug: Emtricitabine/Tenofovir disoproxil fumarate
200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
Drug: Tenofovir disoproxil fumarate
300 mg tablet taken orally daily
Drug: Rifampin
Participants should continue receiving regimen that was prescribed prior to study entry
|
1B: Experimental
Participants will defer ART until 8 to 12 weeks after initiation of their TB treatment. Participants will enroll in Arm 2 after completing Arm 1B.
|
Drug: Rifampin
Participants should continue receiving regimen that was prescribed prior to study entry
|
2: Experimental
Arm 1B participants will enroll in Arm 2 and initiate ART
|
Drug: Efavirenz
600 mg tablet taken orally daily
Drug: Emtricitabine
200 mg tablet taken orally daily
Drug: Emtricitabine/Tenofovir disoproxil fumarate
200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
Drug: Tenofovir disoproxil fumarate
300 mg tablet taken orally daily
Drug: Rifampin
Participants should continue receiving regimen that was prescribed prior to study entry
|
TB is the most important coinfection in the HIV epidemic; the bi-directional relationship between the two diseases is well established. HIV increases the risk for TB acquisition, reactivation, and reinfection, and reduces survival compared to patients with TB alone. In individuals with HIV, TB infection results in reduced survival, increased risk for opportunistic infections, and elevations in HIV replication. Improving the outcome of HIV infected individuals who develop TB is of high importance. Initiating ART shortly after initiating TB treatment may improve outcomes in individuals coinfected with HIV and TB. However, data to support this suggestion are limited. This study will determine the most appropriate time to initiate ART in HIV infected individuals who recently initiated treatment for TB.
This study will last 48 weeks and will comprise two steps. At study entry, participants will undergo clinical assessment, drug adherence training, and blood collection. In Step 1, participants will be randomly assigned to one of two arms. Participants in Arm A will initiate ART within 2 weeks after initiating TB treatment.
Participants in Arm B will defer ART until 8 to 12 weeks after initiation of their TB treatment. In Step 2, Arm B participants will initiate ART; Arm A participants will not enter Step 2. ART will consist of efavirenz and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF); FTC and TDF may be given as individual agents. Drug substitutions may be made for participants who cannot tolerate the specified regimen. Blood collection and clinical assessments will occur at Weeks 4, 8, 12, 16, 24, 32, 40, and 48.
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | Diane Havlir, MD | San Francisco General Hospital and University of California, San Francisco |
Responsible Party: | DAIDS ( Rona Siskind ) |
Study ID Numbers: | ACTG A5221, AACTG A5221 |
Study First Received: | April 19, 2005 |
Last Updated: | August 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00108862 History of Changes |
Health Authority: | United States: Federal Government |
Treatment Naive TB HIV Antiretroviral Agents |
Bacterial Infections Anti-Infective Agents Efavirenz Sexually Transmitted Diseases, Viral Anti-HIV Agents Acquired Immunodeficiency Syndrome Antiviral Agents Immunologic Deficiency Syndromes Reverse Transcriptase Inhibitors Virus Diseases Rifampin |
Gram-Positive Bacterial Infections Anti-Retroviral Agents Emtricitabine HIV Infections Sexually Transmitted Diseases Tenofovir Mycobacterium Infections Tuberculosis Retroviridae Infections Tenofovir disoproxil |
Bacterial Infections Anti-Infective Agents Sexually Transmitted Diseases, Viral Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Infection Reverse Transcriptase Inhibitors Gram-Positive Bacterial Infections Anti-Retroviral Agents Emtricitabine Therapeutic Uses Tenofovir Tuberculosis Retroviridae Infections Nucleic Acid Synthesis Inhibitors |
Tenofovir disoproxil RNA Virus Infections Anti-HIV Agents Immune System Diseases Acquired Immunodeficiency Syndrome Enzyme Inhibitors Antiviral Agents Immunologic Deficiency Syndromes Actinomycetales Infections Pharmacologic Actions Virus Diseases HIV Infections Sexually Transmitted Diseases Lentivirus Infections Mycobacterium Infections |